CHICAGO,
Aug. 23, 2024 /PRNewswire/ -- The Alzheimer's Association welcomes today's decision by the
United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) to approve Leqembi
® (lecanemab) for the treatment of Alzheimer's disease. However, while celebrating this milestone - the first Alzheimer's disease modifying treatment approved in the U.K. - the decision by the National Institute for Health and Care Excellence (NICE) to deny access through the National Health Service (NHS) will deepen global health inequity.
"Today is a day of mixed emotions for many in the U.K.," said Joanne Pike, DrPH, Alzheimer's Association president and CEO. "Today's approval decision could provide people living with this fatal and devastating disease the possibility of more time, but this is only possible if people have access to this treatment."
